The Rx Watchdog newsletter was launched in 2004 to inform key stakeholders about drug pricing issues, as well as legislative and legal actions focused on making drugs more affordable. For many years, the linchpin of the Watchdog newsletters has been AARP's continued monitoring of trends in manufacturer prices for prescription drugs widely used by older Americans.
Over the years, however, the Watchdog has also reported on issues such as states' efforts to collect and post pharmacy prices on the Web; allowing the U.S. Food and Drug Administration to approve generic versions of biologic drugs; and the implications of potential cuts in State Pharmacy Assistance Programs or of increasing barriers to consumer access to less costly generic drugs.
Today, Rx Watchdog continues to focus on "shining a light on the cost and quality of prescription drugs."
Rx Watchdog is distributed electronically to federal and state policy-makers, pharmacy trade groups, consumer groups, think tanks and academia, and state and national media who write about prescription drug marketplace issues.
If you would like to comment on Watchdog generally, or on a particular newletter issue or article, you may leave a comment in the "comments" box below.